Pharmaceuticals
-
Novartis combination therapy Tafinlar® + Mekinist® demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma
Jun 24, 2016News Hour: Novartis announced data from a Phase III study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive advanced melanoma when treated with the first-line combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) compared... -
AMG 334 significantly reduces patients’ monthly migraine days in phase II study of chronic migraine prevention
Jun 24, 2016News Hour: Novartis announced positive first results from the global phase II 20120295 study, investigating the efficacy and safety of the fully human monoclonal antibody AMG 334 (erenumab) in chronic migraine prevention. The study evaluated AMG... -
Sandoz’ etanercept and rituximab biosimilar candidates bioequivalent to originator products
Jun 24, 2016News Hour: Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced results from two key studies comparing its biosimilar etanercept and rituximab candidates with the originator products – Enbrel® and MabThera® respectively. In both... -
Data showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV)
Jun 24, 2016News Hour: Novartis announced Phase III data from RESPONSE-2 showing that Jakavi®(ruxolitinib) helped patients with polycythemia vera (PV), who did not have an enlarged spleen and were resistant to or intolerant of hydroxyurea, achieve superior hematocrit... -
Timely use of Novartis’ Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients
Jun 24, 2016News Hour: A new analysis published in JAMA Cardiology has found that timely and broad adoption of Entresto® (sacubitril/valsartan) by all eligible heart failure patients with reduced ejection fraction (HFrEF) could prevent or postpone more than... -
Roche launches the new cobas e 801 module
Jun 20, 2016News Hour: Roche announced today that its new, dedicated high-volume testing immunoassay solution, the cobas e 801 module, is now available for countries accepting the CE Mark. As diagnostic laboratories evolve to meet growing workloads in an...
